Complete interpretation of ensidipine instructions and medication guide!

Enasidenib is a targeted therapy specifically indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who carry isocitrate dehydrogenase type 2 (IDH2) mutations. As a new type of small molecule IDH2 inhibitor, ensidipine effectively reduces the accumulation of the abnormal metabolite 2-hydroxyglutarate (2-HG) by specifically inhibiting the abnormal metabolic activity of the mutant IDH2 enzyme, thereby restoring the differentiation potential of hematopoietic stem cells. This mechanism has been confirmed in multiple in vitro and in vivo experimental models and is of great significance in preventing the further progression of AML.

The recommended dose of this drug is 100 mg taken orally once a day, regardless of meal time. It is recommended to take it at a similar time every day to maintain a stable blood concentration. Patients need to swallow the tablets completely and are not allowed to chew, crush or break them to avoid affecting their sustained release mechanism or bioavailability. During the treatment process, if the patient misses a dose, he should take it as soon as possible on the same day and continue the normal medication plan the next day, but he should not take the medication again within a short period of time to compensate for the missed dose. It is worth noting that in order to achieve efficacy, it is recommended to continue taking the drug for at least six months. Even if no obvious response is observed early, treatment should not be stopped hastily, because the clinical response of some patients may be delayed for several months.

The efficacy of ensidipine has been demonstrated in multiple clinical studies. According to key research data before the US FDA approval, in a phase I/II trial called AG221-C-001, patients with relapsed or refractory AML with IDH2 mutations had an objective response rate (ORR) of approximately 40% after treatment with ensidipine, of which the complete response (CR) rate exceeded 19%. More importantly, the median duration of remission for patients reached 5.8 months, and some patients even maintained remission for more than a year. This makes ensidipine one of the first targeted options for treating this type of AML patients, especially when traditional chemotherapy is ineffective or patients cannot tolerate chemotherapy, providing a new treatment strategy.

The main adverse reactions of ensidipine include hyperbilirubinemia, differentiation syndrome (Differentiation Syndrome), loss of appetite, vomiting, diarrhea, leukocytosis and electrolyte imbalance. Differentiation syndrome is a potentially fatal but reversible adverse reaction, manifested by fever, dyspnea, pulmonary infiltrates, edema, and hypotension. It usually occurs within the first few weeks of treatment. Once recognized, glucocorticoid treatment must be given immediately and temporary discontinuation or dose reduction may be considered. Another significant adverse reaction is hyperbilirubinemia, which is mainly due to the inhibitory effect of the drug on the UGT1A1 enzyme. It usually manifests as an indirect increase in bilirubin, which is mostly reversible and can be controlled through close monitoring and supportive treatment.

Must be done before using ensidipineIDH2 mutation testing to determine whether the patient is suitable for this drug treatment. During the treatment process, the patient's blood routine, biochemical indicators and disease status need to be monitored regularly to evaluate the efficacy and detect adverse reactions in a timely manner. This drug is currently launched by Celgene overseas, such as the United States, and has obtained orphan drug qualification certification from the FDA. However, its listing and medical insurance reimbursement status in mainland China are not yet clear, and it can only be obtained through special drug channels.

Reference materials:https://www.idhifa.com/